Nyheder

Lundbeckfonden Ventures nyheder

Lund, Sweden, 18:00 CET 28 December 2018 – During December, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 28 December 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 51,795,917. For more information contact: BONESUPPORT AB Emil...
Mette Kirstine Agger
Mette Kirstine Agger, Managing Partner i Lundbeckfonden Ventures, blev interviewet af Labiotech under BIO-europe konferencen, november 2018. Se hele interviewet her:      
November 27, 2018 09:00 AM Eastern Standard Time EDINBURGH, Scotland–(BUSINESS WIRE)–DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra Colposcope used in cervical cancer screening, announced today the appointment of Darin Hammers as Chief Executive Officer and a member of the board of directors. In addition, Michael Gioffredi was appointed as Chief Commercial Officer....
Cambridge, UK and Indianapolis, US – 21 November 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that data and analyses from its positive Phase 3 clinical trial of BARHEMSYS(TM) (intravenous amisulpride) as rescue treatment of established post-operative nausea & vomiting (PONV) have been published (Habib et al1) in the online edition...
Lund, Sweden, 08.00 CET, 19 November 2018 – BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone voids, today announces positive top-line data from the CERTiFy (CERAMENT® Treatment of Tibia Plateau Fracture defects) study comparing CERAMENT|BVF with autologous iliac bone graft (autograft). BONESUPPORT CEO Emil Billback said:” Successfully completing the ground-breaking CERTiFy study, to demonstrate...
SAN DIEGO – November 13, 2018 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that the first patient has been dosed in the Company’s Phase 2 clinical program to evaluate the efficacy and safety of APX001 in the treatment of infections caused by Candida. “Initiating our Phase 2 program for...
Cambridge, UK and Indianapolis, US – 6 November 2018: Acacia Pharma Group plc (“Acacia Pharma” or “the Company”), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces that it has resubmitted its New Drug Application (NDA) for BARHEMSYS(TM) (amisulpride injection) to the US Food and Drug Administration (FDA). On 8 October, the...
Lund, Sverige, 08.00 CET, 7 november 2018 – BONESUPPORT™, ett ledande företag verksamt inom ortobiologi för behandling av hålrum i ben, avger sin delårsrapport för tredje kvartalet 2018. Framgångsrik etablering av ny distributionsstruktur i USA 1 JULI – 30 SEPTEMBER 2018 Nettoomsättningen uppgick till 14,2 MSEK (32,7), en minskning med 56%. Till följd av vår uppsägning i...
Lund, Sweden, 08.00 CET, 1 November 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids will publish its Q3 2018 Interim Report on Wednesday 7 November 2018 at 8am CET. The Company will hold a conference call and an online presentation on the same day at 10am CET. The call...
1 2 3 4 48

Lundbeckfonden Ventures

Nyheder

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994
4. februar 2019
BONESUPPORT and Lund University to present at Orthopaedic Research Society (ORS) 2019 Annual Meeting
1. februar 2019
scPharmaceuticals Inc. Announces Development Agreement with West Pharmaceutical Services for Next-Generation FUROSCIX® On-Body Infusor
29. januar 2019